Goli Samimi1, Britton Trabert2, Máire A Duggan3, Jennifer L Robinson4, Kisha I Coa4, Elizabeth Waibel5, Edna Garcia5, Lori M Minasian2, Mark E Sherman6. 1. National Cancer Institute, Bethesda, MD 20892, USA. Electronic address: goli.samimi@nih.gov. 2. National Cancer Institute, Bethesda, MD 20892, USA. 3. Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Canada. 4. ICF International, Inc., Rockville, MD 20878, USA. 5. The American Society for Clinical Pathology Institute for Science, Technology, and Policy, Washington, DC 20005, USA. 6. Mayo Clinic, Jacksonville, FL 32224, USA.
Abstract
OBJECTIVE: Many high-grade serous carcinomas initiate in fallopian tubes as serous tubal intraepithelial carcinoma (STIC), a microscopic lesion identified with specimen processing according to the Sectioning and Extensive Examination of the Fimbria protocol (SEE-Fim). Given that the tubal origin of these cancers was recently recognized, we conducted a survey of pathology practices to assess processing protocols that are applied to gynecologic surgical pathology specimens in clinical contexts in which finding STIC might have different implications. METHODS: We distributed a survey electronically to the American Society for Clinical Pathology list-serve to determine practice patterns and compared results between practice types by chi-square (χ2) tests for categorical variables. Free text comments were qualitatively reviewed. RESULTS: Survey responses were received from 159 laboratories (72 academic, 87 non-academic), which reported diverse specimen volumes and percentage of gynecologic samples. Overall, 74.1% of laboratories reported performing SEE-Fim for risk-reducing surgical specimens (82.5% academic versus 65.7% non-academic, p < 0.05). In specimens from surgery for benign indications in which initial microscopic sections showed an unanticipated suspicious finding, 75.9% of laboratories reported using SEE-Fim to process the remainder of the specimen (94.8% academic versus 76.4% non-academic, p < 0.01), and 84.6% submitted the entire fimbriae. CONCLUSIONS: Changes in the theories of pathogenesis of high-grade serous carcinoma have led to implementation of pathology specimen processing protocols that include detailed analysis of the fallopian tubes. These results have implications for interpreting trends in cancer incidence data and considering the feasibility of developing a bank of gynecologic tissues containing STIC or early cancer precursors. Published by Elsevier Inc.
OBJECTIVE: Many high-grade serous carcinomas initiate in fallopian tubes as serous tubal intraepithelial carcinoma (STIC), a microscopic lesion identified with specimen processing according to the Sectioning and Extensive Examination of the Fimbria protocol (SEE-Fim). Given that the tubal origin of these cancers was recently recognized, we conducted a survey of pathology practices to assess processing protocols that are applied to gynecologic surgical pathology specimens in clinical contexts in which finding STIC might have different implications. METHODS: We distributed a survey electronically to the American Society for Clinical Pathology list-serve to determine practice patterns and compared results between practice types by chi-square (χ2) tests for categorical variables. Free text comments were qualitatively reviewed. RESULTS: Survey responses were received from 159 laboratories (72 academic, 87 non-academic), which reported diverse specimen volumes and percentage of gynecologic samples. Overall, 74.1% of laboratories reported performing SEE-Fim for risk-reducing surgical specimens (82.5% academic versus 65.7% non-academic, p < 0.05). In specimens from surgery for benign indications in which initial microscopic sections showed an unanticipated suspicious finding, 75.9% of laboratories reported using SEE-Fim to process the remainder of the specimen (94.8% academic versus 76.4% non-academic, p < 0.01), and 84.6% submitted the entire fimbriae. CONCLUSIONS: Changes in the theories of pathogenesis of high-grade serous carcinoma have led to implementation of pathology specimen processing protocols that include detailed analysis of the fallopian tubes. These results have implications for interpreting trends in cancer incidence data and considering the feasibility of developing a bank of gynecologic tissues containing STIC or early cancer precursors. Published by Elsevier Inc.
Authors: David W Kindelberger; Yonghee Lee; Alexander Miron; Michelle S Hirsch; Colleen Feltmate; Fabiola Medeiros; Michael J Callahan; Elizabeth O Garner; Robert W Gordon; Chandler Birch; Ross S Berkowitz; Michael G Muto; Christopher P Crum Journal: Am J Surg Pathol Date: 2007-02 Impact factor: 6.394
Authors: C Bethan Powell; Lee-may Chen; Jane McLennan; Beth Crawford; Charles Zaloudek; Joseph T Rabban; Dan H Moore; John Ziegler Journal: Int J Gynecol Cancer Date: 2011-07 Impact factor: 3.437
Authors: Mark A Eckert; Shawn Pan; Kyle M Hernandez; Rachel M Loth; Jorge Andrade; Samuel L Volchenboum; Pieter Faber; Anthony Montag; Ricardo Lastra; Marcus E Peter; S Diane Yamada; Ernst Lengyel Journal: Cancer Discov Date: 2016-10-07 Impact factor: 39.397
Authors: Britton Trabert; Sally B Coburn; Andrea Mariani; Hannah P Yang; Philip S Rosenberg; Gretchen L Gierach; Nicolas Wentzensen; Kathy A Cronin; Mark E Sherman Journal: J Natl Cancer Inst Date: 2018-07-01 Impact factor: 13.506
Authors: Blanca L Valle; Sebastian Rodriguez-Torres; Elisabetta Kuhn; Teresa Díaz-Montes; Edgardo Parrilla-Castellar; Fahcina P Lawson; Oluwasina Folawiyo; Carmen Ili-Gangas; Priscilla Brebi-Mieville; James R Eshleman; James Herman; Ie-Ming Shih; David Sidransky; Rafael Guerrero-Preston Journal: Cancer Prev Res (Phila) Date: 2020-06-24
Authors: Monica Rodriquez; Ashley S Felix; Mary Anne Brett; Goli Samimi; Máire A Duggan Journal: Int J Gynecol Pathol Date: 2021-08-11 Impact factor: 3.326